Blue Owl Capital's stock has fallen 62% from its peak despite strong revenue and earnings growth, with no signs of a subprime-like crisis. The company's lending portfolio is low-leverage and first-lien, with minimal losses and redemptions, countering panic-driven narratives. Recent results highlight 14% year-over-year fee-related earnings growth, 21% management fee growth over the last twelve months, and $11 billion in new capital raised, including diversification into real assets and digital infrastructure. This suggests a potential asymmetric risk/reward opportunity as market sentiment may be undervaluing Blue Owl's diversified, fee-driven business model.
Silvaco and NVIDIA have teamed up to enhance semiconductor design and manufacturing by integrating NVIDIA's AI and accelerated computing with Silvaco's physics-based simulation technology. This collaboration aims to create high-fidelity digital twins...
Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, was ranked No. 3 on The Medicine Maker Power List 2026 in the Small Molecules category, recognizing his leadership in oncology drug development. Under his guidance, Ascentage Pharma has advanced i...
Wemix suffered a smart contract exploit where attackers minted over 5.2 million unauthorized tokens and moved approximately $724,000 worth of assets across multiple blockchains. This led to the suspension of all bridges connected to its network, halt...
Bitcoin options markets display a clear bullish bias with call options making up 66.26% of total open interest at $33.57 billion, up 1.14% from the previous day. Despite ongoing volatility hedging indicated by significant put option volume, traders a...
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) remains a hold for investors seeking defensive exposure to companies with long-term dividend growth. It provides a 2% starting yield and an 8.57% three-year dividend growth rate, ensuring income s...
